We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ENTA market cap is 181.11M. The company's latest EPS is USD -5.4398 and P/E is -1.56.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 18M | 17.05M | 17.97M | 14.61M | 16.96M |
| Operating Income | -34.89M | -32.77M | -24.19M | -29.85M | -23.54M |
| Net Income | -33.41M | -31.16M | -22.66M | -28.82M | -22.29M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 122.47M | 97.07M | 86.16M | 79.2M | 67.64M |
| Operating Income | -41.64M | -109.57M | -123.84M | -137.21M | -121.69M |
| Net Income | -36.17M | -79M | -121.76M | -133.82M | -116.05M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 428.5M | 413.56M | 398.82M | 376.65M | 348.64M |
| Total Liabilities | 236.62M | 247.44M | 249.91M | 247.84M | 236.83M |
| Total Equity | 191.88M | 166.11M | 148.92M | 128.81M | 111.82M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 486.13M | 438.79M | 375.41M | 462.28M | 376.65M |
| Total Liabilities | 30.55M | 39.36M | 54.08M | 245.54M | 247.84M |
| Total Equity | 455.58M | 399.43M | 321.33M | 216.74M | 128.81M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -24.99M | -53.59M | -68.36M | -78.76M | -16.8M |
| Investing | -13.12M | 45.51M | 39.16M | 58.24M | 68.9M |
| Financing | -7.35M | -13.76M | -20.41M | -27.63M | -4.99M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 7.09M | -70M | -84.78M | -103.15M | -78.76M |
| Investing | 19.83M | 36.99M | 54.9M | -53.58M | 58.24M |
| Financing | 8.98M | 3.08M | 20.03M | 198.13M | -27.63M |
| Market Cap | 181.11M |
| Price to Earnings Ratio | -1.56 |
| Price to Sales Ratio | 2.68 |
| Price to Cash Ratio | 4.86 |
| Price to Book Ratio | 1.41 |
| Dividend Yield | - |
| Shares Outstanding | 21.33M |
| Average Volume (1 week) | 647.33k |
| Average Volume (1 Month) | 542.85k |
| 52 Week Change | -36.92% |
| 52 Week High | 17.80 |
| 52 Week Low | 4.71 |
| Spread (Intraday) | 1.12 (12.13%) |
| Company Name | Enanta Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.enanta.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
